10-Q: Vystar Corporation Reports Q3 2024 Results Amidst Reorganization and Strategic Shift

Vystar Corporation's Q3 2024 results reflect a period of reorganization and strategic refocusing, impacting revenue and profitability.

Summary

• Vystar Corporation reported a net loss of $344,704 for the three months ended September 30, 2024, compared to a net loss of $929,631 for the same period in 2023.
• The company's revenue decreased to $53,094 in Q3 2024 from $60,350 in Q3 2023, a 12% decline.
• Gross profit also decreased to $36,002 in Q3 2024 from $54,765 in Q3 2023, a 34.3% decrease.
• Operating expenses decreased by 21.3% to $293,766 in Q3 2024 from $373,464 in Q3 2023.
• Interest expense increased significantly to $94,196 in Q3 2024 from $12,918 in Q3 2023 due to new term debt.
• For the nine months ended September 30, 2024, the net loss was $1,007,563, compared to $2,728,174 for the same period in 2023.
• Revenue for the first nine months of 2024 was $128,770, a 74.6% decrease from $506,383 in the same period of 2023.
• Gross profit for the first nine months of 2024 was $71,326, a significant decrease from $418,187 in the same period of 2023.
• Operating expenses for the first nine months of 2024 decreased by 14.9% to $916,337 from $1,076,540 in the same period of 2023.
• The company's accumulated deficit stood at approximately $61.6 million as of September 30, 2024.
• Vystar is focusing on its RxAir and Vytex product lines and improving internal reporting systems.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant revenue declines, increased losses, and a going concern warning. While there are some positive aspects like reduced operating expenses, the overall sentiment is negative due to the company's financial instability and reliance on future capital raises.

Positives

• Operating expenses decreased in both the three and nine month periods ended September 30, 2024.
• The net loss decreased in both the three and nine month periods ended September 30, 2024.
• The company is actively working to improve internal controls and financial reporting processes.
• The company is focusing on its core product lines, RxAir and Vytex.

Negatives

• Revenue and gross profit decreased significantly in both the three and nine months ended September 30, 2024.
• Interest expense increased significantly due to new term debt.
• The company has a substantial accumulated deficit of approximately $61.6 million.
• There is substantial doubt about the company's ability to continue as a going concern due to significant losses and negative cash flow since inception.
• The company has a deficit in working capital of approximately $7.3 million.

Risks

• The company's ability to continue as a going concern is uncertain due to significant losses and negative cash flow.
• The company's success depends on achieving projected revenue and obtaining additional financing.
• The company may need to curtail or reorient operations if it cannot achieve projected revenue and obtain additional financing.
• The company is exposed to risks pertinent to the operations of a retailer, including the ability to acquire new customers and maintain a strong brand.
• The company is exposed to broader economic factors such as interest rates and changes in customer spending patterns.
• The company is subject to legal proceedings and claims that have not been fully resolved.

Future Outlook

The company plans to finance future operations using cash on hand, increased revenue from RxAir air purification units, Vytex license fees, and stock issuances. There is no assurance that the company will be able to achieve projected levels of revenue in 2024 and beyond.

Management Comments

• Jamie Rotman took over as CEO to refocus the Company on Vystar's two main product lines, RxAir and Vytex.
• Another objective was to bring the internal reporting systems up to date including procedures to make future reporting and external audits run smoothly.
• Management plans to finance future operations using cash on hand, increased revenue from RxAir air purification units, Vytex license fees and stock issuances to new and existing shareholders.

Industry Context

The company operates in the air purification and natural rubber latex industries, which are subject to market trends, competition, and regulatory changes. The company is also impacted by broader economic factors such as interest rates and changes in customer spending patterns.

Comparison to Industry Standards

• The company's revenue decline of 74.6% for the nine months ended September 30, 2024, is significantly worse than the industry average for companies in the air purification and natural rubber latex sectors.
• The company's gross profit margin of 55.4% for the nine months ended September 30, 2024, is below the industry average for companies in the air purification and natural rubber latex sectors.
• The company's operating expenses as a percentage of revenue are higher than industry benchmarks, indicating a need for cost optimization.
• The company's net loss of $1,007,563 for the nine months ended September 30, 2024, is significantly worse than the industry average for companies in the air purification and natural rubber latex sectors.
• The company's accumulated deficit of approximately $61.6 million is a significant concern compared to industry standards.
• The company's cash position of $27,772 is significantly below the industry average for companies in the air purification and natural rubber latex sectors.
• The company's working capital deficit of approximately $7.3 million is a significant concern compared to industry standards.
• The company's reliance on related party debt is higher than industry benchmarks, indicating a need for diversification of funding sources.
• The company's internal control weaknesses are a significant concern compared to industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to legal proceedings and claims that have not been fully resolved and have arisen in the ordinary course of business.
• The company is involved in ongoing litigation with EMA Financial, Inc., with a cross-appeal filed.

Related Party Transactions

• The company has significant related party transactions with officers, directors, and their affiliated entities.
• Jamie Rotman, the CEO, receives compensation and benefits through an employment agreement.
• Blue Oar Consulting, Inc., owned by Gregory Rotman, provides business consulting services.
• Bryan Stone, a director, receives commissions on RxAir unit sales to a specific customer.
• Steven Rotman, former CEO, has a stock subscription payable balance and reimbursable expenses payable.

Stakeholder Impact

• Shareholders are impacted by the company's significant losses and going concern uncertainty.
• Employees are impacted by the company's financial instability and potential for restructuring.
• Customers may be impacted by the company's ability to continue operations and provide products and services.
• Suppliers may be impacted by the company's financial instability and potential for payment delays.
• Creditors are impacted by the company's financial instability and potential for default.

Next Steps

• The company plans to focus on its RxAir and Vytex product lines.
• The company plans to improve internal reporting systems.
• The company plans to finance future operations using cash on hand, increased revenue from RxAir air purification units, Vytex license fees and stock issuances.
• The company expects to strengthen internal control during 2024 by developing stronger business and financial processes for accounting for transactions.

Key Dates

Keywords

Vystar Corporation, RxAir, Vytex, air purification, natural rubber latex, financial results, Q3 2024, reorganization, strategic shift, going concern, internal controls, financial reporting